Author

Louise Taber

Observed names: L. Taber, Louise Taber, MD

Institution: Arizona Research Center

Observed institutions: Arizona Research Center, Purdue Pharma (United States)

ORCID: 0000-0003-1077-2277

Observed ORCID: 0000-0003-1077-2277

OpenAlex ID: A5008160892

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

2025 · Todd Bertoch, Dominick D’Aunno, et al. · Anesthesiology · 132

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain

2025 · Jessica McCoun, Peter Winkle, et al. · Journal of Pain Research · 73

12-Month safety and effectiveness of once-daily hydrocodone

2015 · Warren Wen, PhD, Louise Taber, MD, et al. · Journal of Opioid Management · 21

A walking model to assess the onset of analgesia in osteoarthritis knee pain

2010 · E. Peeva, C.R. Beals, et al. · Osteoarthritis and Cartilage · 14

Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain

2015 · Louise Taber, Shau Yu Lynch, et al. · Postgraduate Medicine · 9

P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil

2009 · Pierre Tariot, Marwan Sabbagh, et al. · Alzheimer s & Dementia · 7

Safety and Effectiveness of Once-Daily Hysingla Extended-Release Tablets in Patients with Baseline Depression or Anxiety

2017 · Louise Taber, Ellie He, et al. · Pain Management · 3

Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis

2016 · Louise Taber, Stacy Baldridge, et al. · Postgraduate Medicine · 3

(461) Long-term safety and effectiveness of once-daily, single-entity, abuse-deterrent hydrocodone in chronic nonmalignant and nonneuropathic pain: results of a long-term open-label study

2014 · S. Lynch, W. Wen, et al. · Journal of Pain · 2

Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials

2017 · Louise Taber, T. Christopher Bond, et al. · Journal of Pain Research · 1

Pregabalin naproxencarbil in acute post-bunionectomy pain: a randomized clinical trial

2026 · Guang-Liang Jiang, J. Richard Evanson, et al. · PAIN Reports

(457) Effectiveness of Hysingla® ER, a once-daily, single-entity, hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with depression and anxiety

2016 · S. Lynch, L. Taber, et al. · Journal of Pain

(438) A 24-week extension of an open-label, long-term safety study evaluating the safety and effectiveness of once-daily, single-entity, hydrocodone in patients with chronic nonmalignant and non-neuropathic pain

2015 · W. Wen, L. Taber, et al. · Journal of Pain

Works count: 13

Citation count: 265

H-index: 6

I10-index: 4